← /news·[MARKETS]·JUN 20·2 min read

Memento Medicines Raises $93 Million Series A to Advance Dual-Target Retinal Disease Antibody

Boston-based Memento Medicines closed a $93 million Series A round on June 18, 2026, to push a bispecific antibody therapy for retinal diseases into development.

$Tomas Reyes·NewsNTech

share //

$ cat source.txt

globenewswire.com

← back to the feed Subscribe free

// related, decompiled

Tesla shares slide 11% as discount pricing squeezes profits while capex doubles on AI and robotics push

The unit economics of vehicle manufacturing leave little room for price concessions.

Owen Gallagher·2 minJUL 25

[MARKETS]02

AI spending signals send Tesla and Alphabet sharply lower

The constraint investors are now explicitly pricing is this: artificial intelligence infrastructure spending accrues upfront, at scale, and the revenue it is supposed to generate arrives later, with significant uncertain…

Marcus Cole·2 minJUL 25

[MARKETS]03

Cloud gaming's subscriber acquisition gap pushes Amazon and Microsoft toward separate models

The first-session gap has defined the ceiling for cloud gaming since the category emerged: to reach a new player, a service must clear the hardware prerequisite and the subscription decision before a single session occur…

Mara Whitfield·2 minJUL 25